Could a pomegranate metabolite boost cancer immunotherapy?
NCT ID NCT07161310
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests whether urolithin A, a natural compound, can improve how the immune system responds to standard immunotherapy in people with solid tumors like lung cancer or melanoma. About 45 participants who have not had prior cancer treatment will receive either urolithin A or a placebo alongside their immunotherapy. The main goal is to measure changes in immune cells, not to directly treat the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Frankfurt, Medizinische Klinik II, Hämatologie/Onkologie
RECRUITINGFrankfurt, 60590, Germany
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.